Literature DB >> 12614985

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

María del Carmen Serrano1, Anastasio Valverde-Conde, Mónica Chávez M, Samuel Bernal, Rosa María Claro, Javier Pemán, Mercedes Ramirez, Estrella Martín-Mazuelos.   

Abstract

Voriconazole, anidulafungin (VER002, LY303366) and caspofungin are promising antifungal agents which provide a good protection against a variety of fungi, including yeasts and filamentous fungi. In this study, we tested the in vitro efficacy of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B, against different species of Aspergillus spp. isolated from clinical specimens, using a microdilution broth method and following the NCCLS guidelines (document M38-P). We also evaluated the effect that time readings have on MIC results. For caspofungin, we determined the minimun effective concentration (MEC), defined like the lowest concentration of caspofungin causing abnormal hyphal growth. Anidulafungin (VER002, LY303366) was the most active antifungal agent tested with MIC(90) of < or =0,03 mg/L. The activity of voriconazole, and itraconazole very similar with MIC(90) of 0,12 mg/L, 0,12 mg/L respectively. For caspofungin the MEC(90) was of 0,25 mg/L. Amphotericin B was the lest active antifungal agent studied with MIC(90) of 1 mg/L. There were no differences between MIC values at 48 and 72 h. These data demonstrate promising activity of voriconazole, anidulafungin (VER002, LY303366) and caspofungin against Apergillus spp.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614985     DOI: 10.1016/s0732-8893(02)00507-2

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  20 in total

Review 1.  Palliative dental care- a boon for debilitating.

Authors:  Bhavana Sujana Mulk; Raja Lakshmi Chintamaneni; Prabhat Mpv; Sarat Gummadapu; Shyam Sundar Salvadhi
Journal:  J Clin Diagn Res       Date:  2014-06-20

2.  Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.

Authors:  Michael A Thiel; Annelies S Zinkernagel; Jürgen Burhenne; Claude Kaufmann; Walter E Haefeli
Journal:  Antimicrob Agents Chemother       Date:  2006-10-23       Impact factor: 5.191

3.  A review of clinical experience with newer antifungals in children.

Authors:  Renee M Fallon; Jennifer E Girotto
Journal:  J Pediatr Pharmacol Ther       Date:  2008-07

4.  Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.

Authors:  Tawanda Gumbo; George L Drusano; Weiguo Liu; Lei Ma; Mark R Deziel; Michael F Drusano; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

5.  New methods to assess susceptibilities of Aspergillus isolates to caspofungin.

Authors:  Alexander Imhof; S Arunmozhi Balajee; Kieren A Marr
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

6.  In vitro activity of anidulafungin against selected clinically important mold isolates.

Authors:  Zekaver Odabasi; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

7.  In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

8.  Anidulafungin.

Authors:  David Murdoch; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.

Authors:  Ping Liu
Journal:  Antimicrob Agents Chemother       Date:  2012-11-05       Impact factor: 5.191

10.  The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.

Authors:  Abdullah Ayçiçek; Zafer Cetinkaya; Halil Kiyici; Fethullah Kenar; Gülşah Aşik; Nuri Kiraz
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-04-02       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.